This monograph demonstrates empirically how the free-market system of drug pricing is vital to the development of new breakthrough drugs.

Even comparative effectiveness proposals will hamper new drug development.

This paper uses national data for the period 1960 to 2000 to estimate an aggregate private consumer demand for pharmaceuticals in the United States.

The authorestimates the potential long-run economic costs of legalizing drug reimportation.

This paper identifies two mechanisms through which price regulation (or reimportation) may exert an influence on research and development.

In one of a series of events and conversations about the meaning of the American calendar, Amy A. Kass (Hudson Institute) and Leon R. Kass (AEI) seek to restore America's fading national memory with a celebration of the holiday by its original and proper name: Washington's Birthday.

This paper uses aggregate data for the major pharmaceutical companies in the U.S. to study the rate of growth in pharmaceutical R&D intensity over the period from 1952 to 2001.

Congress has introduced several bills on net neutrality, but mostof themare likely to do more harm than good.